A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer
about
Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer.miRNA signature associated with outcome of gastric cancer patients following chemotherapy.Modeling the transcriptional consequences of epidermal growth factor receptor ablation in Ras-initiated squamous cancer.Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy.Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients.Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC).Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins.Array-based pharmacogenomics of molecular-targeted therapies in oncology.The management of EGFR inhibitor adverse events: a case series and treatment paradigm.Profile of selumetinib and its potential in the treatment of melanoma.KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis.Molecular signatures of lung cancer: defining new diagnostic and therapeutic paradigms.Cytosolic high-mobility group box protein 1 (HMGB1) and/or PD-1+ TILs in the tumor microenvironment may be contributing prognostic biomarkers for patients with locally advanced rectal cancer who have undergone neoadjuvant chemoradiotherapy.
P2860
Q33693936-4348BF10-2C9C-4684-9C73-31AF7F2D3AA8Q34082270-382D7CA5-98A6-4435-AC72-31CE3E4A52E3Q35653271-9534959B-F87D-42BD-948B-E89D138F3CD2Q35875892-CDCFFB79-F8ED-4864-AE8C-8A5A367CDBCDQ36671291-75DF9674-28E1-4397-AC8B-38CCCFF6F9ABQ37109905-2BC1BFAF-98A1-4665-AE5D-A53667C2C21DQ37421431-D60BF088-F7E3-4452-A4E7-4F0A487D4C07Q37725990-B1510287-0AB1-4114-840C-94C5D9D78ED5Q37976288-6D94831B-9BBE-4581-9F6E-FD414A074556Q37976416-D0416C84-2064-47B7-8010-4F552EF72054Q38256348-C955797F-5197-4949-ADFD-1A3530E20F9BQ39642103-FFD3A8D4-A836-4536-B785-AB6D518067C0Q44582343-3EF3D57F-8D20-4540-947C-43A382D2DA8EQ47262101-90091D0D-2E2F-4814-AFF5-47CD79B6FCF5
P2860
A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A gene expression predictor of ...... e metastatic colorectal cancer
@ast
A gene expression predictor of ...... e metastatic colorectal cancer
@en
type
label
A gene expression predictor of ...... e metastatic colorectal cancer
@ast
A gene expression predictor of ...... e metastatic colorectal cancer
@en
prefLabel
A gene expression predictor of ...... e metastatic colorectal cancer
@ast
A gene expression predictor of ...... e metastatic colorectal cancer
@en
P2860
P356
P1433
P1476
A gene expression predictor of ...... e metastatic colorectal cancer
@en
P2093
Esther P Black
P2860
P2888
P356
10.1186/1471-2407-9-145
P407
P577
2009-05-13T00:00:00Z
P5875
P6179
1042279615